| Camptosar |
was approved as first-line therapy for the treatment of patients with metastatic colorectal cancer (advanced cancer that has spread beyond the colon or rectum) in combination with 5-fluorouracil/leucovorin (5-FU/LV). Camptosar is associated with myelosuppression and both early (during or shortly after infusion) and late (more than 24 hours after infusion) forms of diarrhea, that may be severe. ...
출처: www.careerstep.com/newsletter/00aprmay/terminology...
|
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|